Progress of long noncoding RNAs in anti-tumor resistance

Hui Zhang; Yuanyuan Wang; Xiaomin Liu; Yanli Li

doi:10.1016/j.prp.2020.153215

Progress of long noncoding RNAs in anti-tumor resistance

Pathol Res Pract. 2020 Nov;216(11):153215. doi: 10.1016/j.prp.2020.153215. Epub 2020 Sep 12.

Authors

Hui Zhang¹, Yuanyuan Wang², Xiaomin Liu¹, Yanli Li³

Affiliations

¹ Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
² Department of Respiratory and Critical Care Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
³ Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China. Electronic address: liyanli@shu.edu.cn.

PMID: 32979688
DOI: 10.1016/j.prp.2020.153215

Abstract

The resistance of cancer cells to anti-cancer drugs is an important reason for the failure of treatment. Overcoming drug resistance can achieve long-lasting and efficient cancer treatment. Long non-coding RNA (lncRNA) is a class of RNA molecules that does not encode protein and has more than 200 nucleotides. LncRNA not only has a regulatory role in the occurrence and development of malignant tumors, but also has been found to have a potential impact on anti-tumor resistance. Abnormal expression of lncRNA can cause tumor cells to develop resistance to anti-tumor drugs. This article reviews the recent research progress of lncRNA in various tumor resistances and the mechanism of lncRNA acting on tumor drug resistance.

Keywords: Cancer; Drug resistance; Long noncoding RNA; Molecular mechanism.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Drug Resistance, Neoplasm / genetics*
Humans
Neoplasms / drug therapy
Neoplasms / genetics*
RNA, Long Noncoding / genetics*

Substances

Antineoplastic Agents
Biomarkers, Tumor
RNA, Long Noncoding